Lava Therapeutics N.V. (LVTX) Stock Price, Quote & News

Company Profile

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prosta...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 85 016 3100

Website: www.lavatherapeutics.com

Address:

Yalelaan 62, Utrecht, Netherlands

Ballz_Deep_In_Gains Jun. 16 at 3:45 AM

$BBAI $CLOV $FFAI $INO $LVTX Another 🤡 with his dogshit calls.

4 · Reply

DavidScott Jun. 16 at 3:41 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $LVTX $CLOV $FFAI $BBAI $INO

0 · Reply

DavidScott Jun. 2 at 3:15 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SPRC $TOON $LVTX $PHUN $TROO

1 · Reply

JarvisFlow May. 15 at 2:07 PM

JMP Securities updates rating for LAVA Therapeutics ( $LVTX ) to Market Perform.

0 · Reply

MoonDT2024 Apr. 21 at 12:55 PM

$FUBO $GME $LVTX $PHUN $NNDM

0 · Reply

mbhatti1981 Apr. 21 at 6:29 AM

$FUBO $GME $LVTX $NNDM $PHUN

0 · Reply

DavidScott Apr. 21 at 3:01 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $FUBO $GME $LVTX $PHUN $NNDM

0 · Reply

Thestocktraderhubzee Apr. 17 at 10:23 AM

WATCHLIST APR 17 2025. $LYFT Lyft Announced It Has Entered Into A Definitive Agreement To Acquire Freenow From BMW Group And Mercedes-benz Mobility For Approximately €175M Or $197M In Cash $DATS DatChat Receives Notice Of Allowance For European Patent Application For Advanced Digital Privacy Technology Titled "Systems And Methods Of Transforming Electronic Content." $TGL Treasure Global Forms Exclusive Strategic Partnership With Mezzofy To Become Sole Distributor Of Its Digital Coupon Platform In Malaysia, Targeting $2M–$4M In Recurring Annual Revenue Within 12 Months $BAC Argus Research Maintains Buy on Bank of America, Lowers Price Target to $47 $LVTX LAVA Therapeutics shares are trading higher after the company announced it received a $5.1 million payment obligation waiver.

1 · Reply

DavidScott Apr. 17 at 3:33 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $HOLO $WWR $LVTX $GEVO $ACB

0 · Reply

DavidScott Apr. 16 at 8:06 PM

$SBEV $HOLO $LVTX $WWR $MIRA = Awesome work everyone! We taught those bears a valuable lesson today. These were our main trades this session! We are looking for more momentum on these names again going into Thursday. If you need any guidance or a mentor, then feel free to message me anytime! ✅🙌 Have a great day everybody! 🎉

1 · Reply

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update

Apr 16, 2025, 7:30 AM EDT - 2 months ago

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

Mar 28, 2025, 7:30 AM EDT - 2 months ago

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Feb 28, 2025, 12:32 PM EST - 3 months ago

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

Jan 10, 2025, 8:23 AM EST - 5 months ago

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

Dec 10, 2024, 7:30 AM EST - 6 months ago

LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

Sep 3, 2024, 8:00 AM EDT - 10 months ago

LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 20, 2024, 7:30 AM EDT - 10 months ago

LAVA Reports Second Quarter 2024 Financial Results and Business Update

Jun 20, 2024, 7:30 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 10, 2024, 7:00 AM EDT - 1 year ago

LAVA Announces Annual Meeting of Shareholders

May 30, 2024, 7:00 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 21, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference

Mar 20, 2024, 7:00 AM EDT - 1 year ago

LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results

Mar 5, 2024, 7:30 AM EST - 1 year ago

LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)

Jan 25, 2024, 7:00 AM EST - 1 year ago

LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®

Nov 16, 2023, 7:00 AM EST - 1 year ago

Lava Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

Sep 6, 2023, 7:11 AM EDT - 1 year ago

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Aug 22, 2023, 7:00 AM EDT - 1 year ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

Jun 14, 2023, 9:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway

Jun 8, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Jun 1, 2023, 4:20 PM EDT - 2 years ago

LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development

Jun 1, 2023, 8:09 AM EDT - 2 years ago

LAVA Therapeutics to Participate in the Jefferies Healthcare Conference

Apr 11, 2023, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Mar 9, 2023, 8:05 AM EST - 2 years ago

LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

$LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium$

Feb 16, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

Feb 9, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Feb 6, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

Jan 23, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU Symposium

Jan 6, 2023, 1:07 PM EST - 2 years ago

LAVA Therapeutics Announces Appointment of New Directors to the Board

Jan 3, 2023, 7:00 AM EST - 2 years ago

LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 10, 2022, 10:00 AM EST - 2 years ago

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 16, 2022, 4:05 PM EST - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

Nov 3, 2022, 4:05 PM EDT - 2 years ago

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 3, 2022, 9:00 AM EDT - 2 years ago

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Nov 1, 2022, 7:00 AM EDT - 2 years ago

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

Oct 18, 2022, 2:32 AM EDT - 2 years ago

LAVA Therapeutics: Assessing A Promising Innovator

Oct 7, 2022, 11:00 AM EDT - 2 years ago

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Sep 26, 2022, 8:00 AM EDT - 2 years ago

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Sep 13, 2022, 4:05 PM EDT - 2 years ago

LAVA Therapeutics Provides Business Update and Reports Second Quarter Financial Results

Sep 7, 2022, 7:41 AM EDT - 3 years ago

LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Jun 16, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Jun 15, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces Two Appointments to its Board of Directors

Jun 2, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the Jefferies Healthcare Conference

Jun 1, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 31, 2022, 4:05 PM EDT - 3 years ago

LAVA Therapeutics Announces Annual Meeting of Shareholders

May 17, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

May 12, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

May 5, 2022, 7:00 AM EDT - 3 years ago

LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

Ballz_Deep_In_Gains Jun. 16 at 3:45 AM

$BBAI $CLOV $FFAI $INO $LVTX Another 🤡 with his dogshit calls.

4 · Reply

DavidScott Jun. 16 at 3:41 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $LVTX $CLOV $FFAI $BBAI $INO

0 · Reply

DavidScott Jun. 2 at 3:15 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SPRC $TOON $LVTX $PHUN $TROO

1 · Reply

JarvisFlow May. 15 at 2:07 PM

JMP Securities updates rating for LAVA Therapeutics ( $LVTX ) to Market Perform.

0 · Reply

MoonDT2024 Apr. 21 at 12:55 PM

$FUBO $GME $LVTX $PHUN $NNDM

0 · Reply

mbhatti1981 Apr. 21 at 6:29 AM

$FUBO $GME $LVTX $NNDM $PHUN

0 · Reply

DavidScott Apr. 21 at 3:01 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $FUBO $GME $LVTX $PHUN $NNDM

0 · Reply

Thestocktraderhubzee Apr. 17 at 10:23 AM

1 · Reply

DavidScott Apr. 17 at 3:33 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $HOLO $WWR $LVTX $GEVO $ACB

0 · Reply

DavidScott Apr. 16 at 8:06 PM

1 · Reply

DavidScott Apr. 7 at 4:37 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $SIDU $NNDM $CLOV $FFAI $LVTX

0 · Reply

JarvisFlow Mar. 31 at 11:00 AM

HC Wainwright & Co. updates rating for LAVA Therapeutics ( $LVTX ) to Neutral, target set at 1.5.

0 · Reply

DavidScott Mar. 31 at 4:16 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $INO $NNDM $LUNR $CLOV $LVTX

0 · Reply

hitmongreen Mar. 28 at 2:37 PM

$LVTX 🤔

0 · Reply

DonCorleone77 Mar. 28 at 11:42 AM

$LVTX Lava Therapeutics expects $1M of expenses related to restructuring plan In February 2025, the Company adopted a restructuring plan to extend its capital resources in connection with initiating a process to evaluate strategic alternatives. As part of the restructuring plan, the Company's board of directors approved a reduction of approximately 30% of the Company's global workforce to better align resources with the Company's focus on the evaluation of strategic options and the Phase 1 study for LAVA-1266. The Company expects approximately $1.0 million of expenses related to the restructuring to be incurred during the six months ended June 30, 2025, of which approximately $0.3 million of cash payments are expected to be made during 2025.

0 · Reply

DonCorleone77 Mar. 28 at 11:37 AM

$LVTX Lava Therapeutics sees cash runway into 2027 As of December 31, 2024, LAVA had cash, cash equivalents, and investments of $76.6 million, compared to cash, cash equivalents, and investments of $95.6 million as of December 31, 2023. The Company believes its current cash, cash equivalents and investments will be sufficient to fund operations into 2027.

0 · Reply

DonCorleone77 Mar. 28 at 11:37 AM

$LVTX Lava Therapeutics reports Q4 EPS (14c) vs. (24c) last year Reports Q4 revenue $4.99M vs. $353,000 last year. "LAVA's approach to maximize shareholder value in 2025 will focus on evaluating strategic options while continuing to enroll patients in our ongoing Phase 1 study of LAVA-1266, and supporting our pharma partnerships," said Steve Hurly, Chief Executive Officer of LAVA. "The Phase 1 study of LAVA-1266 as a potential treatment for acute myeloid leukemia and myelodysplastic syndrome is progressing. Looking ahead, with a strong cash balance, we believe LAVA is well-positioned to unlock strategic opportunities, and we look forward to updating investors with our progress throughout the year."

0 · Reply

Whiskey1679 Mar. 10 at 3:23 AM

Whiskeys picks. All new picks approx. 4 am Monday morning! Go to my profile and see the pinned post for Friday's winners!! Charles Schwab let's you trade at that hour! Best in trading. Always take your profits. Have a good weekend folks. Top stocks volume % this past week etc. $LVTX $AMC $GEVO

1 · Reply

DavidScott Mar. 10 at 3:03 AM

On watch tomorrow (swing trading) // Part 3 🔥📈📚 $CAN $LVTX $AMC $FRSX $NNDM

0 · Reply

DavidScott Mar. 7 at 3:53 AM

On watch tomorrow (swing trading) // Part 2 🔥📈📚 $TOON $GREE $NNVC $LVTX $HOLO

1 · Reply

NotBornYesterday Mar. 6 at 11:13 PM

$LVTX Est. company will end 1Q w/ ~$2.20-$2.30/sh in cash...or 55-65% higher from here. Then add potential enterprise value for the two partnered products and LAVA-1266. Effort is certainly no guarantee of success, but clinicaltrials.gov suggests PFE making meaningful investment in PF-08046052. Phase 1 trial has twenty-five sites open for enrollment in US/UK, with a whopping 275 patient target enrollment. Big numbers for an early-stage trial.

0 · Reply

PenkeTrading Mar. 6 at 10:45 AM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of LAVA Therapeutics NV. Is that bullish or bearish? $LVTX #LAVA #RsiOverbought #NASDAQ

0 · Reply

Market Cap	34.46M
Revenue (ttm)	11.98M
Net Income (ttm)	-25.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-209.60%
Debt to Equity Ratio	0.18

Volume	6,800
Avg Vol	44,250
Day's Range	N/A - N/A
Shares Out	26.31M
Stochastic %K	10%
Beta	0.48
Analysts	Sell
Price Target	$1.83